This article has Open Peer Review reports available.
Matrix metalloproteinase-10 promotes tumor progression through regulation of angiogenic and apoptotic pathways in cervical tumors
© Zhang et al.; licensee BioMed Central Ltd. 2014
Received: 13 January 2014
Accepted: 25 March 2014
Published: 3 May 2014
Cancer invasion and metastasis develops through a series of steps that involve the loss of cell to cell and cell to matrix adhesion, degradation of extracellular matrix and induction of angiogenesis. Different protease systems (e.g., matrix metalloproteinases, MMPs) are involved in these steps. MMP-10, one of the lesser studied MMPs, is limited to epithelial cells and can facilitate tumor cell invasion by targeting collagen, elastin and laminin. Enhanced MMP-10 expression has been linked to poor clinical prognosis in some cancers, however, mechanisms underlying a role for MMP-10 in tumorigenesis and progression remain largely unknown. Here, we report that MMP-10 expression is positively correlated with the invasiveness of human cervical and bladder cancers.
Using commercial tissue microarray (TMA) of cervical and bladder tissues, MMP-10 immunohistochemical staining was performed. Furthermore using a panel of human cells (HeLa and UROtsa), in vitro and in vivo experiments were performed in which MMP-10 was overexpressed or silenced and we noted phenotypic and genotypic changes.
Experimentally, we showed that MMP-10 can regulate tumor cell migration and invasion, and endothelial cell tube formation, and that MMP-10 effects are associated with a resistance to apoptosis. Further investigation revealed that increasing MMP-10 expression stimulates the expression of HIF-1α and MMP-2 (pro-angiogenic factors) and PAI-1 and CXCR2 (pro-metastatic factors), and accordingly, targeting MMP-10 with siRNA in vivo resulted in diminution of xenograft tumor growth with a concomitant reduction of angiogenesis and a stimulation of apoptosis.
Taken together, our findings show that MMP-10 can play a significant role in tumor growth and progression, and that MMP-10 perturbation may represent a rational strategy for cancer treatment.
The extracellular microenvironment is an integral and dynamic scaffold that dictates cell function and cell fate for both normal and cancer cells. Cancer invasion and metastasis develop through a series of steps that involve the loss of cell to cell and cell to matrix adhesion, degradation of extracellular matrix and induction of angiogenesis. A number of protease systems, including the matrix metalloproteinases (MMPs) are involved in these steps. MMPs are essential regulators of the tissue microenvironment through their ability to control extracellular matrix (ECM) turnover . The MMP family is comprised of at least 24 members that can collectively process virtually any component of the ECM , thereby influencing basic cellular processes that underlie cancer development, e.g., cell dissociation, cell death and cell division.
Based on our previous biomarker studies, we were interested in studying MMP-10, a relatively understudied MMP in cancer biology. MMP-10 (also known as stromelysin 2) is generally limited to epithelial cells  and can target pro-MMP-1, -7, -8, -9, -13, collagen type III, IV, V, gelatin, elastin, fibronectin, proteoglycans and laminin , activities that have been shown to promote tumor cell invasion . It has been demonstrated that MMP-10 expression is increased in several human tumors of epithelial origin, including gastric cancer [6, 7], bladder cancer , esophageal cancer , skin cancer  and non-small cell lung cancer (NSCLC) . These findings suggest that MMP-10 may play an important role in the development and progression of malignant tumors.
In this study, we monitored MMP-10 expression in cohorts of human tumor tissues, and investigated the mechanistic role of this MMP using a panel of in vitro and in vivo studies. We found that MMP-10 expression is positively correlated with an invasive phenotype in both human cervical and bladder cancers. Experimentally, we found that MMP-10 expression is tightly controlled and can be mediated by three-dimensional culture. We show that MMP-10 regulates migration/invasion capability, endothelial cell tube formation, and induces the expression of key angiogenic and metastatic factors (e.g., MMP-9; hypoxia inducible factor-1 alpha, HIF-1α; chemokine (C-X-C motif) receptor 2, CXCR2; and plasminogen activator inhibitor-1, PAI-1). Furthermore, MMP-10 activity causes resistance to apoptosis via both the intrinsic and extrinsic apoptotic pathways. Lastly, we demonstrate that targeting MMP-10 in a human cervical cancer xenograft model with siRNA inhibited angiogenesis and induced apoptosis, resulting in a significant reduction in the growth of xenograft tumors. These results suggest that MMP-10 has distinct, multiple roles in tumor cell-matrix interactions that favor tumor progression.
Immunohistochemcal (IHC) staining of tissue microarrays
With IRB approval from MD Anderson Cancer Center Orlando, commercial tissue microarrays (TMA) (CR805 and BL2082, BL1002, US Biomax, Inc., Rockville, MD) constructed from clinical samples obtained from a cohort of 80 patients (70 cervical cancers; 67 adenocarcinoma and 3 squamous cell carcinoma and 10 benign cervical tissues) and from a cohort of 258 patients (188 bladder cancers and 70 benign bladder tissues) were examined by immunohistochemical staining. Clinical staging was recorded for cervical cancer using International Federation of Gynecology and Obstetrics (Stages 0-IV) and for bladder cancer using TNM staging (Stage I-IV). Protocol and antibody details are available in Additional file 1.
Cells and reagents
Human cervical cancer cell line HeLa (adenocarcinoma from ATCC, Manassas, VA) and benign human bladder cell line, UROtsa (a generous gift from Dr. Donald Sens at the University of North Dakota School of Medicine, Grand Forks, ND) were available for analysis. HeLa cells were maintained in RPMI 1640 media and UROtsa cells were maintained in DMEM media as previously described . Primary human umbilical vein endothelial cell (HUVEC, Cambrex) was cultured in EBM-2 basal media supplemented with EGM-2 MV Kit (Lonza) containing 2% FBS. HUVEC cells of passage 6 to 8 were used. To ensure optimal siRNA delivery in xenograft tumors, in vivo-jetPEI (Polyplus-transfection Inc. NYC, NY), a linear polyethylenimine, was used in conjunction with siRNA .
Gene transfection for stable cell lines
A plasmid with a sequence verified human MMP-10 cDNA cloned within pCMV6-Entry vector and plasmid with vector alone (Origene Technologies) were transfected into HeLa cells using Fugene HD transfection reagent (Roche Diagnostics) to create HeLa-MMP-10OE and HeLaEmpty, respectively. Stable transfectants were selected with 1,200 μg/ml of G418 (Life Technologies, Inc.) for 14 days and subcloned by limiting dilution in 96-well plates. Integration of the transfected gene into chromosome was confirmed by reverse transcriptase-PCR (data not shown). Stable cell lines were maintained in media containing 500 μg/ml of G418 for HeLa clones (HeLa-MMP-10OE and HeLaEmpty).
Transfection of small interfering RNA (siRNA)
UROtsa cells were transfected for 6 hrs with synthesized MMP-10 siRNA (UROtsa-MMP-10KD-1 and UROtsa-MMP-10KD-2) or negative control siRNA (UROtsa-MMP-10Scr) (Life Technologies) using 6 well plates with a 100-pmol of siRNA and 5 μl of lipofectamine 2000 (Life Technology). Forty-eight hrs after transfection, transfected cells were replated for further experiments. MMP-10 siRNA sequences are listed in Additional file 1.
Quantitative reverse transcriptase-PCR
RNA was extracted from cells using RNeasy mini kit (Qiagen) as per manufacturer’s instructions. Conversion to cDNA was achieved through High Capacity cDNA Reverse Transcription kit (Life Technologies). Quantitative reverse transcriptase (RT)-PCR was carried out using ABI 7300 Real-Time PCR System (Life Technologies) in a 20 μl reaction volume containing 1 μl of the first-strand cDNA, 1 μM of gene-specific TaqMan primer and probe mix. Primer sets can be found in Additional file 1. Relative fold changes in mRNA levels were calculated after normalization to GAPDH using the comparative Ct method .
Thirty micrograms of total cell lysate from the parental cervical cancer cell line HeLa and parental urothelial cell line UROtsa as well as 30 μg of total cell lysate from the following clones: HeLa-MMP-10OE, HeLaEmpty, UROtsa-MMP-10KD1&2 and UROtsa-MMP-10Scr, were electrophoresed on 10% SDS-polyacrylamide gels containing 1 mg/ml casein (Sigma, St. Louis, MO) under non-reducing conditions. After electrophoresis and SDS removal, MMP-10 renaturation was achieved by washing the gel for 1 hr in buffer containing 2.5% Triton-X 100, 50 mM tris pH 7.4, 5 mM CaCl2, and 1 μM ZnCl2. Gels were then incubated in a reaction buffer containing 50 mM Tris pH 7.4, 5 mM CaCl2, 1 μM ZnCl2 and 0.02% NaN3 pH 8.0 for 18 hrs at 37°C, followed by staining with Coomassie blue. MMP-10 activity was indicated by the degradation of casein. Gels were photographed using the KODAK Gel Logic 200 Imaging System with Carestream Molecular Imaging Software Standard Edition v220.127.116.11 (Carestream Health, Rochester, NY).
Cell migration and invasion assays
Migration assays were performed in 6 well two-tier invasion chambers (Collaborative Biomedical Products, Bedford, MA, USA), using a protocol similar to that used successfully by our group . Polycarbonate membranes were coated with 4 mg/ml growth factor reduced Matrigel (BD Biosciences, San Jose, CA) as described for invasion assays, control inserts (migration only) contained no coating. Two separate experimental designs were tested. First, HeLa-MMP-10OE, HeLaEmpty and UROtsa-MMP-10KD1&2, UROtsa-MMP-10Scr cells were added to each insert at a density of 105 cells/ml/well in RPMI media. The lower chamber contained RPMI media with 10% FBS as chemoattractant. After incubation in a humidified incubator in 5% CO2 at 37°C for 24 hrs, the cells on the top of the polycarbonate membrane were removed. The cells attached to the bottom of the membrane stained for 1 hr with cell viability indicator Calcein AM Fluorscent Dye (BD Biosciences, Franklin Lakes, NJ) and quantified using the FLUOstar OPTIMA at 495 mm excitation and 515 nm emission (BMG LABTECH Inc., Cary, NC).
In additional, HUVEC cells were added to each insert at a density of 105 cells/ml/well in RPMI media. The lower chamber contained conditioned media from HeLa-MMP-10OE, HeLaEmpty, UROtsa-MMP-10KD1&2 and UROtsa-MMP-10Scr. After 24 hrs, the HUVEC cells on the top of the polycarbonate membrane were removed, while the HUVEC cells attached to the bottom of the membrane were stained for 1 hr with cell viability indicator Calcein AM Fluorscent Dye and quantified using the FLUOstar OPTIMA. For the migration and invasion assays, at least three independent experiments consisting of each condition tested in triplicate wells was used to calculate mean ± SD values.
Endothelial cell tube formation assays
Matrigel (BD Biosciences) was added to 96 well plates (40 μl per well) and allowed to solidify for 30 min at 37°C as previously described . HUVEC cells were seeded on top of Matrigel in triplicates at a density of 104 cells per well in conditioned media from cultured HeLa-MMP-10OE, HeLaEmpty, UROtsa-MMP-10KD1&2 and UROtsa-MMP-10Scr and allowed to incubate for 6 hrs. Next, images of capillary tube formation were captured using Leica DMIL inverted microscope. The angiogenic activities were quantitatively evaluated by measuring the total tube length of capillary tube in at least four viewed fields per well. At least three independent experiments consisting of each condition tested in triplicate wells was used to calculate mean ± SD values.
RT2Profiler PCR arrays for angiogenesis and metastasis
Cellular RNA from HeLaEmpty and HeLa-MMP-10OE was recovered and converted to cDNA as described above. RT2 Profiler ‘human angiogenesis’ PCR arrays, (Catalog # PAHS-024ZA; SABiosciences) and RT2 Profiler ‘human metastasis’ PCR arrays, (Catalog # PAHS-028ZA; SABiosciences) were analyzed in duplicate according to the manufacturer's instructions (http://www.sabiosciences.com/pcrarraydataanalysis.php) by quantitative reverse transcriptase (RT)-PCR carried out using ABI 7300 Real-Time PCR system (Life Technologies). The specificity of the SYBR Green assay was confirmed by melting curve analysis. Relative fold changes in mRNA levels were calculated after normalization to housekeeping control gene targets using the comparative Ct method.
Caspase activity assay
HeLa-MMP-10OE and HeLaEmpty cells were lysed in caspase assay buffer containing 50 mM HEPES (pH 7.5), 100 mM NaCl, 2 mM EDTA, 0.1% CHAPS, 10% sucrose and 5 mM DTT. Aliquots of 6 mg of crude cell lysate were incubated with caspase-3 substrate Ac-DEVD-AMC (Pharmingen, San Diego, CA) at 37°C for 30 min. The caspase-3 activity was quantified in a FLUOstar Optima Reader (BMG LABTECH, Ortenberg, Germany) with excitation at 380 nm and emission at 440 nm. At least three independent experiments consisting of each condition tested in triplicate wells was used to calculate mean ± SD values.
Annexin V apoptosis assay
HeLa-MMP-10OE and HeLaEmpty cells were assessed in a LIVE/DEAD Annexin V apoptotic assay (BD Biosciences, Franklin Lakes, NJ) by flow cytometry. Furthermore, resistance to apoptosis was also determined in these same cells by exposing the cells to 1 μM of staurosporine (an agent capable of inducing apoptosis) for 5 hrs. In brief, after 5 hrs of exposure to staurosporine, cells were trypsinized, washed with 1 X PBS, and stained with propidium iodide (PI) in tandem with an APC-conjugated annexinV antibody according to the manufacturer’s instructions (BD Biosciences, San Jose, CA) and quantitated via flow cytometry using the BD FACScaliber with Cell Quest Pro Software (BD Biosciences, San Jose, California) and FlowJo (TreeStar Inc., Ashland, OR). Viable cells were negative for both annexin V and PI, early apoptotic cells exhibit externalization of phosphatidylserine and were annexin V positive but have an intact plasma membrane and were PI negative, while dead and damaged cells which have subsequently lost their membrane integrity were positive for both annexin V and PI.
Mitochondrial membrane potential analysis
Analysis of mitochondrial membrane potential was performed as previously reported by our group . Briefly, for the analysis of mitochondrial membrane potential (DCm), HeLa-MMP-10OE and HeLaEmpty cells were seeded at 5 x 105 cells in 10 cm tissue culture dishes for 24 hrs. Cells were then treated with 1 μM of staurosporine for 0, 1, 5 and 18 hrs. Next, cells were trypsinized, washed with 1 x PBS, incubated with medium containing JC-1 dye (10 μg/ml) for 20 min at 37°C. Lastly, the cells were washed and resuspended in 1 ml PBS for fluorescent flow cytometry analysis using FACScan flow cytometer (Becton Dickinson) measuring at least 104 gated cells. Mitochondrial depolarization is indicated by a decrease in orange/green fluorescence ratio. All mitochondrial membrane potential analyses were performed in triplicate.
Animal care was in compliance with the recommendations of The Guide for Care and Use of Laboratory Animals (National Research Council) and approved by our local IACUC at the University of Central Florida and MD Anderson Cancer Center Orlando. First, the subcutaneous tumorigenicity assay was performed in athymic BALB/c (nu/nu) mice, 6 to 8 wks old purchased from Harlan Laboratories (Indianapolis, IN) by inoculating 106 HeLa cells as described previously [17, 18]. After two weeks, mice were divided randomly into four treatment groups (control, human siRNA MMP-10; 10 μg of siRNA with 1.2 μl of in vivo-jetPEI at a N/P ratio of 6 according to the manufacturer’s protocol, mouse siRNA MMP-10; 10 μg of siRNAs with 1.2 μl of in vivo-jetPEI at a N/P ratio of 6 and combination of human and mouse siRNA MMP-10; 5 μg of human siRNA and 5 μg of mouse siRNA with 1.2 μl of in vivo-jetPEI N/P ratio of 6) and treatment was initiated. siRNA therapy was administered intratumorally twice weekly for five weeks. Control mice received 10 μg of non-target siRNA mixed with 1.2 μl of in vivo-jetPEI N/P ratio of 6 on the same schedule. At least 10 animals were in each group. At the termination of the experiment, mice were sacrificed and tumors resected for IHC analysis.
Immunohistochemical (IHC) analysis of xenograft tumors
All data are expressed as mean ± standard deviation (SD). Statistical analyses were conducted using GraphPad Prism 5.0 (GraphPad Software, Inc.). For most comparisons, a 2-tailed unpaired Student t test or Mann-Whitney U test was conducted. The comparison between MMP-10 expression in low-grade, high-grade, low stage and high stage cancer was calculated using Fisher’s exact test. Differences were considered statistically significant at p < 0.05.
MMP-10 expression is upregulated in cancer tissues
We have previously reported a significant increase in the expression of MMP-10 transcripts in shed urothelia from patients bearing bladder tumors relative to healthy controls , and we subsequently confirmed that increased soluble MMP-10 protein levels were indicative of bladder cancer in two large, independent studies [21, 22]. In this study, we evaluated MMP-10 expression through immunohistochemical staining of a commercial bladder cancer TMA (70 benign samples and 188 cancer samples). Similar staining patterns to those found in the cervical cancers were noted in human bladder cancers (Additional file 2: Figure S1A-I). Specifically, 41 of the 71 samples from muscle invasive bladder cancer (MIBC) had moderate or high expression for MMP-10, whereas 30 samples had low or no expression. From the 68 non-muscle invasive bladder cancer (NMIBC) samples, 24 had moderate or high expression and 44 had low or no expression (p < 0.01 - Additional file 2: Figure S1I), indicating that MMP-10 expression increased in MIBC compared to NMIBC.
MMP-10 expression stimulates migration, and invasion
MMP-10 influences endothelial cell behavior
We also evaluated the ability of MMP-10 to influence the migration and invasion of human endothelial cells. HUVEC cells were tested for movement towards conditioned media from parental HeLa, HeLaEmpty, and HeLa-MMP-10OE cells in the assay described above. For HUVEC cells, the conditioned media associated with HeLa-MMP-10OE caused an increase in migration (p = 0.013) and invasion (p = 0.002) compared to conditioned media from HeLaEmpty cells (Figure 3C). No significant difference in migratory or invasive potential was noted in HUVEC cells exposed to conditioned media from UROtsa-MMP-10KD-1 and UROtsa-MMP-10KD-2 compared to UROtsa-MMP-10Scr or parental UROtsa cells (data not shown).
As a surrogate for potential effects on angiogenesis, we set out to investigate whether MMP-10 expression might influence endothelial tube formation. Conditioned media from the test cell lines was utilized in an in vitro tube formation assay. The total length of tube-like structures formed by HUVECs on growth factor-reduced Matrigel was significantly enhanced by treatment with conditioned media from HeLa-MMP-10OE cells compared to HeLaEmpty cells (~220%, Figure 3D). Conversely, the total length of tube-like structures was significantly reduced when HUVECs were treated with conditioned media from UROtsa-MMP-10KD-1 and UROtsa-MMP-10KD-2 (~72% and ~68%, respectively; Figure 3E) compared to UROtsa-MMP-10Scr.
MMP-10 influences apoptosis
MMP-10 siRNA therapy inhibits xenograft tumor growth
Mice in each test group were injected intratumorally twice weekly with appropriate siRNA. At the end of the 5-week study, untreated HeLa xenografts, and xenografts treated with a scrambled mouse and human control siRNA reagent mix, reached an average volume of 833 mm3 and 882 mm3, respectively (Figure 6B). HeLa xenografts treated with human MMP-10 siRNA reached an average volume of 629 mm3 (29% reduction compared to control siRNA, p < 0.001), while HeLa xenografts treated with mouse MMP-10 siRNA established tumors of 545 mm3 volume (38% reduction compared to control siRNA, p < 0.001). HeLa xenografts treated with a combined human and mouse MMP-10 siRNA mix established tumors of only 474 mm3, a 46% reduction compared to control (p < 0.001), however, this was not significantly different from either human siRNA MMP-10 or mouse siRNA MMP-10 treatment alone (Figure 6B). A clear reduction in MMP-10 expression was identified in xenograft tumors treated with either human or mouse siRNA MMP-10 (Figure 6C & D). Interestingly, when tumors were treated with either human or mouse MMP-10 siRNA alone, a reduction in the expression of the other species MMP-10 was also noted (Figure 6D). Cross reactivity between the species-specific siRNAs was not noted in vitro (data not shown), thus, we speculate that there is some positive feedback link between mouse stromal MMP-10 and HeLa tumor cell MMP-10 production.
Expression levels of the vasculature marker CD31 were monitored in xenograft sections to establish a microvessel density (MVD) index. Analyses revealed a severe reduction of CD31 positivity in HeLa xenograft tumors treated with either human or mouse MMP-10 siRNA. MVD calculated in xenografts treated with the human MMP-10 siRNA, the mouse MMP-10 siRNA, and the combination of human and mouse MMP-10 siRNA groups, revealed a reduction of 50%, 66% and 73%, respectively, relative to control siRNA treatment (Figure 6E). Lastly, the expression level of caspase-3 was evaluated to estimate an apoptotic index (AI). AI of xenografts treated with the human MMP-10 siRNA, the mouse MMP-10 siRNA, and the combination of human and mouse MMP-10 siRNA confirmed an increase of 38%, 45% and 87%, respectively, compared to control siRNA treatment (Figure 6E). However, the combination of human and mouse MMP-10 siRNA did not result in significantly altered MVD or AI relative to those treated with human or mouse MMP-10 siRNA alone. The in vivo observations corroborate the in vitro findings and confirm a role for MMP-10 in the provision of a pro-tumor growth environment through an influence on angiogenesis and apoptosis.
Our findings reveal that MMP-10 expression can induce the expression of key molecules implicated in angiogenesis, metastasis and apoptosis, major mechanisms involved in the establishment and progression of malignant tumors. Though MMP-10 is well characterized biochemically, compared to other MMPs, little is known about MMP-10 in human cancers. Here, we are the first to report the relative increased expression of MMP-10 in human cervical cancer compared to benign tissue, and that expression correlates with the invasive phenotype of malignant cervical tumors. Given that we have recently demonstrated that MMP-10 expression at the RNA  and protein level [21, 22] is increased in urine samples obtained from patients with bladder cancer, so there appears be a trend of association between malignancy and MMP-10. Within this study, analysis of 188 tumor specimens confirmed that MMP-10 protein expression was increased in human bladder tumors, and, as in cervical cancer study, a correlation between more aggressive bladder cancers and MMP-10 expression was noted (Additional file 2: Figure S1). Only one small study has previously reported the expression of MMP-10 in human bladder tumors. In that study, Seargent et al., demonstrated that MMP-10 was predominantly present in the epithelial component of tumor tissue, and that bladder cancer had significantly greater levels of MMP-10 than benign bladder specimens. However, the investigators could not demonstrate a difference in MMP-10 expression between low stage and high stage disease, possibly due to the small (n = 60) sample size . Limited data are available for MMP-10 expression in cervical tissue. However in a small study, Vazquez-Ortiz et al. reported that overexpression of MMP-10 was observed to be consistently overexpressed in invasive cervical cancer biopsies associated by cDNA array. Validation on an independent, large cohort was not performed . We must stress that HPV status was not reported on the commercial TMA utilized in our study. It would be interesting to investigate whether MMP-10 expression is correlated with disease prognosis in cervical and bladder cancers, as it has been in esophageal carcinoma , current studies to address this are underway.
MMP-10 (also known as stromelysin 2) is generally limited to epithelial cells and its regulation is tightly controlled . For example, MMP-10 is not present in intact normal skin, but is expressed during cutaneous injury and repair where it is localized to the migrating keratinocytes at the wound edge, alluding to its role as a pro-invasion molecule . In the HeLa cervical cancer cell line, MMP-10 was not expressed in culture. However, when HeLa cells were grown in a 3D matrix (data not shown), or as a xenograft tumor (Figure 6A), MMP-10 expression was induced. This is similar to the report by Mishra et al., who demonstrated that A549 human lung cancer cells grown in an ex vivo 3D model expressed significantly more MMP-10 than when grown as a monolayer culture . Though benign (as defined by inability to form xenograft tumors), the UROtsa cell line has been transformed by SV40 , and thus has a non-functional p53. This could account for the high level of MMP-10 expression, supporting a role for p53 in MMP-10 expression, originally noted by Meyer et al. .
A considerable amount of information has accumulated to suggest that the role of MMPs in cancer is far more complicated than initially presumed. One such role in cancer is related to apoptosis. MMP activity may have proapoptotic or antiapoptotic effects depending on the local cellular production and availability of proteolytically released and activated death-inducing and/or growth and survival factors . For example, proapoptotic effects can be due to degradation of ECM proteins that serve as ligands for specific classes of integrins. In the absence of the ligand, integrins can no longer trigger signals necessary for epithelial and endothelial survival thus resulting in apoptosis. Alternatively, ECM degradation can result in the release of IGF-1, which could directly promote tumor cell resistance to proapototic signals. In our study, HeLa cells (p53 wild-type) were found to be more resistant to apoptosis when MMP-10 was expressed. This resistance to apoptosis was associated with changes in the expression of key molecules in both the intrinsic (e.g., reduction in Bax, Bak and cleaved caspase 8 and an increase in Bcl-xl) and extrinsic apoptotic pathway (e.g., reduction in FasL and cleaved caspase 8).
An interesting co-expression relationship that we were able to confirm was that between MMP-10 and PAI-1. PAI-1 is an important endogenous inhibitor of urokinase-type plasminogen activator. Specifically, PAI-1 normally functions as part of the plasminogen activation (PA) system, which includes the serine protease uPA (urokinase-type plasminogen activator), its receptor uPA-R, tPA (tissue plasminogen activator) and inhibitors PAI-1 and PAI-2 . PAI-1 expression may be regulated by many intrinsic factors (e.g., cytokines and growth factors) and extrinsic factors (e.g., cellular stress) . Although the canonical function of PAI-1 has been known as an inhibitor of uPA to maintain clot formation  it is now regarded as a pleiotropic factor exerting diverse cellular effects, many related to tumorigenesis; cellular proliferation, migration, invasion, adhesion and angiogenesis. The deregulation of PAI-1 has been correlated to several tumor types (e.g., breast, colorectal, lung and bladder) and has been associated as a poor prognostic factor [34–40]. Previous studies have reported a positive correlation between MMP-10 and PAI-1 [41–43]. Similar, we report an increase of both MMP-10 and PAI-1 in voided urine samples from subjects with bladder cancer [21, 22]. Interesting, Wilkins et al. reported that the addition of PAI-1 blocks collagen degradation as well as the conversion of MMP-10 to its catalytically active form. Thus there exist MMP-10/PAI-1/plasmin dependent proteolytic axis that enhances ECM degradation and facilitates angiogenesis and invasion. Further characterization of this axis may have far reaching implications for therapeutic targeting of human malignancies.
In a series of in vitro and in vivo experiments, MMP-10 activity was shown to be pivotal in the tumor growth in a mouse model of cancer, and the expression of this MMP is associated with the upregulation of key molecules related to angiogenesis, metastasis, and apoptosis, creating a milieu favorable to the survival and expansion of malignant lesions. Furthermore, demonstration of a correlation between MMP-10 expression and invasive cervical and bladder cancers supports a role for MMP-10 in human tumor progression. These data suggest that MMP-10 may have value as a novel biomarker and/or provide a molecular target for therapeutic intervention.
This study was supported by a grant from the James and Esther King Biomedical Research Program (CJR).
This work was funded by the James and Esther King Biomedical Team Science grant - 1KT-01 (CJR).
- Hojilla CV, Mohammed FF, Khokha R: Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Canc. 2003, 89: 1817-1821. 10.1038/sj.bjc.6601327.View ArticleGoogle Scholar
- Egeblad M, Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002, 2: 161-174. 10.1038/nrc745.View ArticlePubMedGoogle Scholar
- Madlener M, Mauch C, Conca W, Brauchle M, Parks WC, Werner S: Regulation of the expression of stromelysin-2 by growth factors in keratinocytes: implications for normal and impaired wound healing. Biochem J. 1996, 320: 659-664.View ArticlePubMedPubMed CentralGoogle Scholar
- Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T: Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem. 2003, 253: 269-285. 10.1023/A:1026028303196.View ArticlePubMedGoogle Scholar
- Krampert M, Bloch W, Sasaki T, Bugnon P, Rülicke T, Wolf E, Bloch W, Sasaki T, Bugnon P, Rülicke T, Wolf E: Activities of the matrix metalloproteinase stromelysin-2 (MMP-10) in matrix degradation and keratinocyte organization in wounded skin. Mol Biol Cell. 2004, 15: 5242-5254. 10.1091/mbc.E04-02-0109.View ArticlePubMedPubMed CentralGoogle Scholar
- Aung PP, Oue N, Mitani Y, Nakayama H, Yoshida K, Noguchi T, Bosserhoff AK, Yasui W: Systematic search for gastric cancer-specific genes based on SAGE data: melanoma inhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer. Oncogene. 2006, 25: 2546-2557. 10.1038/sj.onc.1209279.View ArticlePubMedGoogle Scholar
- Eck M, Schmausser B, Scheller K, Brändlein S, Müller-Hermelink HK: Pleiotropic effects of CXC chemokines in gastric carcinoma: differences in CXCL8 and CXCL1 expression between diffuse and intestinal types of gastric carcinoma. Clin Exp Immunol. 2003, 134: 508-515. 10.1111/j.1365-2249.2003.02305.x.View ArticlePubMedPubMed CentralGoogle Scholar
- Seargent JM, Loadman PM, Martin SW, Naylor B, Bibby MC, Gill JH: Expression of matrix metalloproteinase-10 in human bladder transitional cell carcinoma. Urology. 2005, 65: 815-820. 10.1016/j.urology.2004.11.016.View ArticlePubMedGoogle Scholar
- Mathew R, Khanna R, Kumar R, Mathur M, Shukla NK, Ralhan R: Stromelysin-2 overexpression in human esophageal squamous cell carcinoma: potential clinical implications. Canc Detect Prev. 2002, 26: 222-228. 10.1016/S0361-090X(02)00035-1.View ArticleGoogle Scholar
- Kerkelä E, Ala-aho R, Lohi J, Grénman R, M-Kähäri V, Saarialho-Kere U: Differential patterns of stromelysin-2 (MMP-10) and MT1-MMP (MMP-14) expression in epithelial skin cancers. Br J Canc. 2001, 84: 659-669. 10.1054/bjoc.2000.1634.View ArticleGoogle Scholar
- Zhang X, Zhu S, Luo G, Zheng L, Wei J, Zhu J, Hu S: Expression of MMP-10 in lung cancer. Anticancer Res. 2007, 27: 2791-2795.PubMedGoogle Scholar
- Miyake M, Goodison S, Giacoia EG, Rizwani W, Ross S, Rosser CJ: Influencing factors on the NMP-22 urine assay: an experimental model. BMC Urol. 2012, 12: 23-10.1186/1471-2490-12-23. doi:10.1186/1471-2490-12-23View ArticlePubMedPubMed CentralGoogle Scholar
- Ito T, Shimada Y, Kan T, David S, Cheng Y, Mori Y, Agarwal R, Paun B, Jin Z, Olaru A, Hamilton JP, Yang J, Abraham JM, Meltzer SJ, Sato F: Pituitary tumor-transforming 1 increases cell motility and promotes lymph node metastasis in esophageal squamous cell carcinoma. Canc Res. 2008, 68: 3214-3218. 10.1158/0008-5472.CAN-07-3043.View ArticleGoogle Scholar
- Cao W, Yacoub S, Shiverick KT, Namiki K, Sakai Y, Porvasnik S, Urbanek C, Rosser CJ: Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation. Prostate. 2008, 68: 1223-1231. 10.1002/pros.20788.View ArticlePubMedGoogle Scholar
- Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29: e45-10.1093/nar/29.9.e45.View ArticlePubMedPubMed CentralGoogle Scholar
- Anai S, Sakamoto N, Sakai Y, Tanaka M, Porvasnik S, Urbanek C, Cao W, Goodison S, Rosser CJ: Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for prostate cancer. Urol Oncol. 2011, 29: 421-429. 10.1016/j.urolonc.2009.04.009.View ArticlePubMedGoogle Scholar
- Namiki K, Goodison S, Porvasnik S, Allan RW, Iczkowski KA, Urbanek C, Reyes L, Sakamoto N, Rosser CJ: Persistent exposure to Mycoplasma induces malignant transformation of human prostate cells. PLoS One. 2009, 4: e6872-10.1371/journal.pone.0006872. doi:10.1371/journal.pone.0006872View ArticlePubMedPubMed CentralGoogle Scholar
- Anai S, Goodison S, Shiverick K, Hirao Y, Brown BD, Rosser CJ: Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts. Mol Canc Ther. 2007, 6: 101-111. 10.1158/1535-7163.MCT-06-0367.View ArticleGoogle Scholar
- Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G: Tumor angiogenesis: a new significant and independent prognostic indicator in early stage breast carcinoma. J Natl Canc Inst. 1992, 84: 1875-1887. 10.1093/jnci/84.24.1875.View ArticleGoogle Scholar
- Urquidi V, Goodison S, Cai Y, Sun Y, Rosser CJ: A candidate molecular biomarker panel for the detection of bladder cancer. Canc Epidemiol Biomarkers Prev. 2012, 21: 2149-2158. 10.1158/1055-9965.EPI-12-0428.View ArticleGoogle Scholar
- Goodison S, Chang M, Dai Y, Urquidi V, Rosser CJ: A multi-analyte assay for the non-invasive detection of bladder cancer. PLoS One. 2012, 7 (10): e47469-10.1371/journal.pone.0047469.View ArticlePubMedPubMed CentralGoogle Scholar
- Rosser CJ, Ross S, Chang M, Dai Y, Mengual L, Zhang G, Kim J, Urquidi V, Alcaraz A, Goodison S, Rosser CJ: Multiplex protein signature for the detection of bladder cancer in voided urine samples. J Urol. 2013, 5347: 4581-4583.Google Scholar
- Zucker S, Cao J, Chen WT: Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene. 2000, 19: 6642-6650. 10.1038/sj.onc.1204097.View ArticlePubMedGoogle Scholar
- Meyer E, Vollmer JY, Bovey R, Stamenkovic I: Matrix metalloproteinases 9 and 10 inhibit protein kinase C-potentiated, p53-mediated apoptosis. Canc Res. 2005, 65: 4261-4272. 10.1158/0008-5472.CAN-04-2908.View ArticleGoogle Scholar
- Vázquez-Ortíz G, Ciudad CJ, Piña P, Vazquez K, Hidalgo A, Alatorre B, Garcia JA, Salamanca F, Peralta-Rodriguez R, Rangel A, Salcedo M: Gene identification by cDNA arrays in HPV-positive cervical cancer. Arch Med Res. 2005, 36: 448-458. 10.1016/j.arcmed.2005.04.016.View ArticlePubMedGoogle Scholar
- Liu H, Qin YR, Bi J, Guo A, Fu L, Guan XY: Overexpression of matrix metalloproteinase 10 is associated with poor survival in patients with early stage of esophageal squamous cell carcinoma. Dis Esophagus. 2012, 25: 656-663. 10.1111/j.1442-2050.2011.01284.x.View ArticlePubMedGoogle Scholar
- Sternlicht MD, Werb Z: How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001, 17: 463-516. 10.1146/annurev.cellbio.17.1.463.View ArticlePubMedPubMed CentralGoogle Scholar
- Mishra DK, Sakamoto JH, Thrall MJ, Baird BN, Blackmon SH, Ferrari M, Kurie JM, Kim MP: Human lung cancer cells grown in an ex vivo 3D lung model produce matrix metalloproteinases not produced in 2D culture. PLoS One. 2012, 7: e45308-10.1371/journal.pone.0045308. doi:10.1371/journal.pone.0045308View ArticlePubMedPubMed CentralGoogle Scholar
- Rossi MR, Masters JR, Park S, Todd JH, Garrett SH, Sens MA, Somji S, Nath J, Sens DA: The immortalized UROtsa cell line as a potential cell culture model of human urothelium. Environ Health Perspect. 2001, 109: 801-808. 10.1289/ehp.01109801.View ArticlePubMedPubMed CentralGoogle Scholar
- McCawley LJ, Matrisian LM: Matrix metalloproteinases: they're not just for matrix anymore!. Curr Opin Cell Biol. 2001, 13: 534-540. 10.1016/S0955-0674(00)00248-9.View ArticlePubMedGoogle Scholar
- Rijken DC: Plasminogen activators and plasminogen activator inhibitors: biochemical aspects. Baillieres Clin Haematol. 1995, 8: 291-312. 10.1016/S0950-3536(05)80269-0.View ArticlePubMedGoogle Scholar
- Pyke C, Kristensen P, Ralfkiaer E, Eriksen J, Danø K: The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Canc Res. 1991, 51: 4067-4071.Google Scholar
- Stefansson S, Haudenschild CC, Lawrence DA: Beyond fibrinolysis: the role of plasminogen activator inhibitor-1 and vitronectin in vascular wound healing. Trends Cardiovasc Med. 1998, 8: 175-180. 10.1016/S1050-1738(98)00003-6.View ArticlePubMedGoogle Scholar
- Harbeck N, Kates RE, Schmitt M, Gauger K, Kiechle M, Janicke F, Thomassen C, Look MP, Foekens JA: Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Canc. 2004, 5: 348-352. 10.3816/CBC.2004.n.040.View ArticleGoogle Scholar
- Duffy MJ: Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem. 2002, 48: 1194-1197.PubMedGoogle Scholar
- Berger DH: Plasmin/plasminogen system in colorectal cancer. World J Surg. 2002, 26: 767-771. 10.1007/s00268-002-4050-8.View ArticlePubMedGoogle Scholar
- Pavey SJ, Hawson GA, Marsh NA: Impact of the fibrinolytic enzyme system on prognosis and survival associated with non-small cell lung carcinoma. Blood Coagul Fibrinolysis. 2001, 12: 51-58. 10.1097/00001721-200101000-00008.View ArticlePubMedGoogle Scholar
- Palmirotta R, Ferroni P, Savonarola A, Martini F, Ciatti F, Laudisi A, Sini V, Del Monte G, Guadagni F, Roselli M: Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer. Thromb Res. 2009, 124: 403-408. 10.1016/j.thromres.2009.02.014.View ArticlePubMedGoogle Scholar
- Bashar H, Urano T, Fukuta K, Pietraszek MH, Hata M, Suzuki K, Suzuki K, Kawabe K, Takada Y, Takada A: Plasminogen activators and plasminogen activator inhibitor 1 in urinary tract cancer. Urol Int. 1994, 52: 4-8. 10.1159/000282560.View ArticlePubMedGoogle Scholar
- Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodriguez J: Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol. 2000, 164: 680-684. 10.1016/S0022-5347(05)67280-1.View ArticlePubMedGoogle Scholar
- Fang H, Placencio VR, DeClerck YA: Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic function. J Natl Canc Inst. 2012, 104: 1470-1484. 10.1093/jnci/djs377.View ArticleGoogle Scholar
- Wilkins-Port CE, Ye Q, Mazurkiewicz JE, Higgins PJ: TGF-beta1 + EGF-initiated invasive potential in transformed human keratinocytes is coupled to a plasmin/MMP-10/MMP-1-dependent collagen remodeling axis: role for PAI-1. Canc Res. 2009, 69: 4081-4091.View ArticleGoogle Scholar
- Freytag J, Wilkins-Port CE, Higgins CE, Carlson JA, Noel A, Foidart JM, Higgins SP, Samarakoon R, Higgins PJ: PAI-1 regulates the invasive phenotype in human cutaneous squamous cell carcinoma. J Oncol. 2009, 2009: 963209-View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/14/310/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.